Acidic tumor microenvironment (proton-mediated extracellular acidity)

An acidic tumor microenvironment is a hallmark of solid tumors, arising from increased glycolytic metabolism (Warburg effect), poor perfusion, hypoxia, and overproduction of acidic metabolites (lactic acid, CO₂)[1][2][4][5]. The extracellular pH in tumors drops to 6.0–6.9, much lower than normal tissue (pH ~7.4), due to proton export via transporters (such as NHE-1, H⁺-ATPase, monocarboxylate transporters, and carbonic anhydrase IX)[1][2][4]. Acidic extracellular pH promotes cancer progression through enhanced invasion, metastasis, extracellular matrix degradation, immune evasion, altered gene expression, angiogenesis, and therapy resistance[1][3][5][6]. While targeting acidity as such is not “targeting a molecule” (and thus not a canonical drug target like a receptor or enzyme), drug development has focused on neutralizing tumor acidity or inhibiting acid–base regulators. Acidic microenvironment is a critical factor in cancer biology and therapeutic resistance, but is not a molecule, protein, or receptor, and thus is not itself a proper “therapeutic target” under typical molecular pharmacology definitions[4][5]. **Note:** "Acidic microenvironment / Protons" refers to a physicochemical property and not a discrete molecular entity. While it is not a canonical target (such as an enzyme or receptor), the microenvironment and proton-associated acidity are therapeutically relevant—but the actual molecular targets are the acid/base transporters and pH-regulating enzymes. Thus, this entry is best classified as invalid/incomplete as a drug target per strict molecular definitions[3][4][5].

Other names

Acidic microenvironmentExtracellular acidityTumor acidityTumor pHExtracellular protonsAcidic extracellular pH

Buffering or neutralization of tumor acidity to inhibit invasion/metastasis[3]; Inhibition of acid-base regulators (e.g., NHE-1, carbonic anhydrase CAIX, monocarboxylate transporter)[3][5]